# LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

> **NCT00805194** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1314 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** placebo plus docetaxel
- **DRUG:** BIBF 1120 plus docetaxel

## Key facts

- **NCT ID:** NCT00805194
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-03
- **Primary completion:** 2010-11-02
- **Final completion:** 2017-11-13
- **Target enrollment:** 1314 (ACTUAL)
- **Last updated:** 2018-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00805194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00805194, "LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00805194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*